Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Anika Therapeutics (ANIK) Work In Process (2016 - 2018)

Anika Therapeutics (ANIK) has disclosed Work In Process for 8 consecutive years, with $5.9 million as the latest value for Q3 2018.

  • Quarterly Work In Process fell 9.38% to $5.9 million in Q3 2018 from the year-ago period, while the trailing twelve-month figure was $5.9 million through Sep 2018, down 9.38% year-over-year, with the annual reading at $6.1 million for FY2017, 9.05% up from the prior year.
  • Work In Process for Q3 2018 was $5.9 million at Anika Therapeutics, down from $6.3 million in the prior quarter.
  • The five-year high for Work In Process was $6.6 million in Q3 2017, with the low at $2.2 million in Q2 2014.
  • Average Work In Process over 5 years is $4.8 million, with a median of $5.6 million recorded in 2016.
  • The sharpest move saw Work In Process soared 94.43% in 2016, then dropped 9.38% in 2018.
  • Over 5 years, Work In Process stood at $3.0 million in 2014, then surged by 85.99% to $5.7 million in 2015, then fell by 1.71% to $5.6 million in 2016, then grew by 9.05% to $6.1 million in 2017, then fell by 1.88% to $5.9 million in 2018.
  • According to Business Quant data, Work In Process over the past three periods came in at $5.9 million, $6.3 million, and $5.9 million for Q3 2018, Q2 2018, and Q1 2018 respectively.